ANI Pharmaceuticals (ANIP) just put fresh numbers on the table, reporting third quarter and nine month 2026 results along with a slight trim to full year revenue guidance that gives investors new data to weigh. At a share price of $67.41, ANI Pharmaceuticals has slipped about 11% over the past 90 days and is down 14% year to date, while the 1 year total shareholder return is lower at 25% in decline. However, the 3 and 5 year total shareholder returns remain positive, suggesting that the...
Ani Pharmaceuticals’ Iluvien uveitis Phase 4 SYNCHRONICITY trial met endpoints, boosting BCVA and reducing CS. Read more here.
Detailed price information for Stryker Corp (SYK-N) from The Globe and Mail including charting and trades.
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences: Event2026 Wells Fargo Healthcare Conference DateThursday, September 10, 2026 Time1:30 p.m. ET WebcastClick here EventMorgan Stanley 24th Annual Global Healthcare Co
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of
This is the newest page. Registered accounts read further back.